CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously
This article was originally published in The Gray Sheet
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.
You may also be interested in...
Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.
Beta amyloid positron emission tomography scans to help diagnose dementia would only be covered by Medicare as part of a clinical trial under a proposed national coverage decision. Eli Lilly requested broader coverage for its Amyvid PET imaging agent.
MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.